Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0819 in Fibromyalgia
NCT03056690Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibromyalgia (FM) comparing ASP0819 with Placebo (2 arms). Primary endpoint: Change From Baseline to Week 8 in Mean Daily Average Pain Score Assessed by NRS. Started Mar 2017; status: completed.
02
Drugs
ASP0819
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT03056690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056690.